ArticleScientific reports2016
Complete De Novo Assembly of Monoclonal Antibody Sequences.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed.
- Foundation model enables interpretable open and error-tolerant searching for mass spectrometry-based proteomics.Bioinformatics (Oxford, England) · 2026Article
- Enhancing the Recovery of Antioxidant Compounds from Microalgae-Cyanobacteria Consortia Through Alcalase Hydrolysis: A Focus on Bioactive Peptides.Marine drugs · 2026Article
- PowerNovo2: A generative flow-based approach to non-autoregressive de novo peptide sequencing.PLoS computational biology · 2026Article
- Generalizable Direct Protein Sequencing With InstaNexus.Molecular & cellular proteomics : MCP · 2026Article
- XA-Novo: high-throughput mass spectrometry-based de novo sequencing technology for monoclonal antibodies and antibody mixtures.Nature communications · 2026Article
- Cryo-EM structures of light chain fibrils from abdominal fat biopsies of multiple myeloma patients.Nature communications · 2026Article
- Biopsy-resolved cryo-EM structures of amyloid fibrils provide molecular insights into AL amyloidosis.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Applications and Prospects of Artificial Intelligence in ProteomicsCurrent protein & peptide science · 2026Review
- Article
- Article
- Sequencing of Polyclonal Antibodies by Integrating Intact Mass, Middle-Down, and De Novo Bottom-Up Mass Spectrometry.Molecular & cellular proteomics : MCP · 2025Article
- Cost-Effective Method for Full-Length Sequencing of Monoclonal Antibodies from Hybridoma Cells.Antibodies (Basel, Switzerland) · 2025Article
- Article
- Epitope and Paratope Mapping of a SUMO-Remnant Antibody Using Cross-Linking Mass Spectrometry and Molecular Docking.Journal of proteome research · 2025Article
- Article
- MicroalgaFoods (Basel, Switzerland) · 2025Article
- π-PrimeNovo: an accurate and efficient non-autoregressive deep learning model for de novo peptide sequencing.Nature communications · 2025Article
- Identification of natural Zika virus peptides presented on the surface of paediatric brain tumour cells by HLA class I.PloS one · 2025Article
- De Novo Sequencing of Peptides from Tandem Mass Spectra and Applications in Proteogenomics.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Crucial Parameters for Immunopeptidome Characterization: A Systematic Evaluation.International journal of molecular sciences · 2024Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
De novo protein sequencing is one of the key problems in mass spectrometry-based proteomics, especially for novel proteins such as monoclonal antibodies for which genome information is often limited or not available. However, due to limitations in peptides fragmentation and coverage, as well as ambiguities in spectra interpretation, complete de novo assembly of unknown protein sequences still remains challenging. To address this problem, we propose an integrated system, ALPS, which for the first time can automatically assemble full-length monoclonal antibody sequences. Our system integrates de novo sequencing peptides, their quality scores and error-correction information from databases into a weighted de Bruijn graph to assemble protein sequences. We evaluated ALPS performance on two antibody data sets, each including a heavy chain and a light chain. The results show that ALPS was able to assemble three complete monoclonal antibody sequences of length 216-441 AA, at 100% coverage, and 96.64-100% accuracy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.